Abstract: Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for gastric cancer (GC). However, the occurrence of resistance to 5-FU treatment poses a major problem for its clinical efficacy. In this study, we found that the NFκB-signaling pathway can mediate 5-FU resistance in GC cells. We developed a 5-FU-resistant GC cell line named SGCR/5-FU and found that the 5-FU-induced resistance increased cytosolic IκBα degradation and promoted NFκB nuclear translocation in GC cells. These findings were further confirmed by the activation of the NFκB survival-signaling pathway in clinical specimens. Curcumin, a natural compound, can reverse 5-FU resistance and inhibits proliferation in GC cells by downregulating the NFκB-signaling pathway. Moreover, it can also decrease the expression level of TNFα messenger RNA. Flow cytometry and Western blot analysis results showed that the combination of curcumin and 5-FU caused synergistic inhibition of growth and induction of potent apoptosis in the resistant cancer cell lines in vitro. In conclusion, our results demonstrate that the combination of 5-FU and curcumin could be further developed as a potential therapy for human GC.
Introduction
Gastric cancer (GC) is the fourth most common type of cancer and the second highest cause of cancer-related death worldwide. 1 Fluorouracil (5-FU) has been used as the standard of care for advanced GC and has been found to increase overall survival by 6% and reduce the risk of mortality by 18%. 2 However, as most patients relapse with lethal drug-resistant disease, the efficacy of 5-FU for GC is limited in clinical treatment. 3 To overcome 5-FU resistance, a combined therapy of docetaxel, cisplatin, and 5-FU has been developed and has demonstrated improved efficacy, particularly for advanced GC. 4 However, it is very difficult to deal with intrinsic or acquired resistance of certain tumors in 5-FU therapy. Furthermore, the increased toxicity of the aforementioned combination therapy reduces patients' ability to tolerate the chemotherapy regimen. Currently, the precise mechanisms for 5-FU resistance in GC remain elusive. Therefore, identifying mechanisms underlying the drug resistance is essential for developing novel approaches to improve the clinical outcome of 5-FU therapy. We hypothesize that combination therapies targeting specific cellular pathways may provide a rationale to abrogate resistance and decrease the toxicity of chemotherapy for a better long-term outcome in GC treatment.
NFκB, a transcription factor, typically exists as a heterodimeric complex composed of the Rel-family proteins p50 and p65 (RelA). IκBα, an inhibitor of NFκB, secludes 
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Kang et al the p65-p50 heterodimer in the cytoplasm under the inactive condition. Once the cell is provoked, stimulus-mediated phosphorylation of IκBα and subsequent proteolytic degradation cause the release and nuclear accumulation of RelA-p50 dimer, where it binds to specific promoters and subsequently regulates carcinoma-related gene transcription. 5 Tumor necrosis factor alpha (TNFα) has long been known to induce NFκB signaling. It is also an intricate linker between inflammation and cancer through mediating the process of apoptosis and cell-mediated immunity. 6 In a previous study, upregulation of TNFα transcription was shown specifically to promote tumor progression in some human tumors. 6, 7 Highly metastatic tumor cells could be rescued from apoptosis by activating autocrine TNFα. Another study has also ascribed intrinsic drug resistance to production and secretion of TNFα by cancer cells. 8 It has been reported that the aberrant production of TNFα may also induce chemoresistance. 7 The transcription factor NFκB has also been linked with many functions. [9] [10] [11] [12] Moreover, owing to constitutive NFκB activity conferring resistance to gemcitabine in pancreatic carcinoma and paclitaxel in prostate cancer, 9,13 several treatment strategies have been applied to block NFκB signaling as a new adjuvant approach in chemotherapy. These findings suggest that NFκB inhibitors could reduce chemoresistance and may be used in combination with chemotherapeutic drugs as a novel therapy for GC.
Curcumin, a natural compound from turmeric, has an excellent safety profile. It has been found to have antitumor, anti-inflammatory, and apoptotic properties both in vitro and in vivo. [14] [15] [16] Studies have demonstrated that curcumin has the potential to be combined with chemotherapeutics for GC. 17, 18 These reports focused mainly on the role of curcumin in resistant GC cells through the activation of survivin and STAT3 signaling. In recent clinical trials, the combination of curcumin and standard docetaxel chemotherapy has demonstrated significant clinical improvements in patients with advanced breast cancer and castration-resistant prostate cancer. 19, 20 However, a 5-FU and curcumin combination treatment for resistant GC cells has not been tried in clinical trials. In this study, we attempted to investigate whether curcumin could inhibit activation of the NFκB survival-signaling pathway to reverse GC resistance and enhance the efficacy of 5-FU chemotherapy. Our results showed that the combination of 5-FU and curcumin caused markedly synergistic inhibition of growth and induction of apoptosis in SGC and SGCR/5-FU cell lines. Further study of the underlying mechanism indicates that curcumin may overcome 5-FU resistance in GC cells by downregulating the NFκB-signaling pathway. The results may provide a rationale for further development of a 5-FU and curcumin combination therapy as a new approach to reverse GC acquired resistance and induce GC-cell death. 
Materials and methods
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curcumin mediates chemosensitization to 5-FU 4%-12% sodium dodecyl sulfate polyacrylamide-gel electrophoresis gels and then transferred to nitrocellulose membranes (Bio-Rad Laboratories). After being blocked with fresh 5% nonfat milk in Tris-buffered saline-polysorbate 20 for 1.5 hours at room temperature, the membrane was incubated at 4°C overnight with the specific primary antibody and at room temperature for 1 hour with the secondary antibody, followed by three washes. Immunoreactive bands were visualized using the enhanced chemiluminescence kit. The density of the immunoreactive bands was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
immunohistochemistry
Histological sections (5 μM) were deparaffinized and rehydrated. Antigen retrieval was performed by heating the slides in a 10 mM citrate buffer in a pressure cooker. Subsequently, the specimens were washed in 0.01 M phosphate-buffered saline (PBS), treated with 3% hydrogen peroxide, and washed in 0.01 M PBS again. Blocking was performed with 3% BSA in 0.01 M PBS, and then the specimens were incubated with the respective reagents overnight at 4°C. For the detection of the expression of IκBα protein, anti-IκBα polyclonal IgG antibody (1:200; Santa Cruz Biotechnology) was used as a primary antibody, and donkey antirabbit IgG-HRP antibody (1:200; Santa Cruz Biotechnology) was used as a secondary antibody. Thereafter, these slides were stained with diaminobenzidine (Beyotime, Haimen, China) and counterstained with hematoxylin. Sections 5 μm thick containing both tumor and normal tissues taken from each patient were used for IκBα immunohistochemistry.
Immunofluorescent staining
Cells were grown on sterilized coverslips in a six-well dish overnight. Cells were fixed with 4% paraformaldehyde for 10 minutes, washed with PBS, and blocked with 3% BSA for 1 hour at room temperature. All cell preparations were incubated with the primary antibodies against p65 (1:200) overnight at 4°C, then PE-labeled goat antirabbit antibody (1:400) IgG was used as a secondary antibody for 1 hour at room temperature. Afterward, nuclei were stained with DAPI. The images were captured with confocal microscopy (400× amplification, Eclipse Ti; Nikon, Tokyo, Japan).
Resistance index and cell viability via MTT assay
Cells were incubated in 96-well plates with an initial culture medium of 4×10 3 cells per well and cultured with various concentrations of curcumin in 96-well plates for 72 hours. In the combination treatment, drugs (curcumin and 5-FU) were simultaneously added to the culture medium. Cells were treated with an MTT 5 mg/mL (20 μL per well) solution for 4 hours at 37°C. After this period, the MTT was carefully aspirated, and formazan crystals were dissolved by adding 150 μL of DMSO to each well. The results were analyzed using spectrophotometry at 490 nm wavelength. Growth inhibition was assayed by MTT, and half-maximal inhibitory concentration (IC 50 ) values were calculated by GraphPad Prism 6 software. The resistance index was calculated as the ratio between the IC 50 of SGCR/5-FU cells and that of SGC cells.
Development of 5-FU-resistant sublines from the SGC cell lines
5-FU-treated conditioned media (5-FU-CM) cells collected from fresh SGC cells incubated with 5-FU (5-FU, 10 μM) for 72 hours were used to prepare SGC-7901R/5-FU (SGCR/5-FU) cell lines. CM cells were added to fresh SGC cells, followed by further 5-FU treatment (low concentrations increased successively) for more than 3 months. 21, 22 This process was monitored by MTT assay at regular intervals. The procedure to develop 5-FU-resistant sublines from SGC cell lines was as follows. Cells were serially passaged initially with low concentrations of 5-FU (about 1/10 IC 50 , 2 μM) and sequentially cultured in increasing concentrations of about 1-1.5 μM 5-FU every two weekdays. MTT was measured every half a month or month to see the degree of 5-FU drug-resistance changes and at the same time to freeze some drug-resistant cells. Cells that were able to survive stably in the medium containing 10 μM of 5-FU were considered to be 5-FU-resistant and named SGCR/5-FU cells. Experiments with these cell sublines were performed and the cells maintained in the 5-FU-free medium for 2-3 weeks.
clonogenic survival assay 
RNA interference
Small-interfering RNA (siRNA) pools against NFκB p65 and negative control were purchased from GE Healthcare. Cells were grown to 60% confluence in six-well plates and transfected with Lipofectamine RNAiMax (Thermo Fisher Scientific) as indicated in the manufacturer's instructions. After incubation for 6 hours at 37°C, the transfection media were replaced with normal growth media, and the cells were allowed to recover for an additional 24 hours before experimental treatments.
Determination of caspase-3 activity
Cellular apoptosis was analyzed with a caspase 3 activity kit (Beyotime).
Real-time quantitative polymerase chain reaction (PCR)
Total RNA from the tissues and cells was extracted using Trizol reagent (Thermo Fisher Scientific). Reverse-transcription (RT) quantitative PCR was performed with an M-MLV Platinum RT-qPCR kit (Thermo Fisher Scientific). The primers used for real-time PCR to detect TNFα (forward primer 5′-CCCAGGGACCTCTCTCTAATC-3′, reverse primer: 5′-ATGGGCTACAGGCTTGTCACT-3′) were designed on an iQ5 Multicolor real-time PCR detection system (BioRad Laboratories) and normalized to internal control β-actin messenger RNA (mRNA).
gc-tumor samples
The series of 32 clinical GC samples were obtained from the First Affiliated Hospital of Wenzhou Medical University.
Normal gastric tissues that were more than 5 cm away from the edge of tumors were randomly selected. 
Results nFκB signal-pathway activation promotes 5-FU resistance
We investigated the possible signal pathways responsible for drug resistance to 5-FU chemotherapy for GC. First, we developed a 5-FU-resistant SGCR/5-FU GC cell line by chronically exposing parental cells to increasing doses of 5-FU over 3 months. As shown in Figure 1A , ( Figure 1E and F) . Additionally, we found that the nuclear transcription factor NFκB p65 was activated in resistant GC cells ( Figure 1G-I) . These results indicated that NFκB activation was a major factor that mediated the resistance to 5-FU in GC cells. Then, we sought to elucidate further the role of NFκB p65 as a determinant of therapy response by RNA-interference assay. The proliferation assay showed that knockdown of NFκB p65 by siRNA in SGCR/5-FU cells increased 5-FU sensitivity, as opposed to the cells transfected with the control siRNA ( Figure 1J -L). 
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Curcumin overcomes resistance of SGC cells to 5-FU treatment
Based on significant NFκB activation in 5-FU-resistant SGC cells and the fact that curcumin has been reported to suppress NFκB activation, 23 we tested whether curcumin could improve the sensitization of SGCR/5-FU cancer cells. We treated SGCR/5-FU-resistant cells with 5-FU, single-agent curcumin, or a combination (5-FU + curcumin), followed by MTT assay. As shown in Figure 2A , curcumin (at 2.4 μM) synergistically increased the efficacy of 5-FU in SGCR/5-FU cells at all 5-FU doses in MTT assays. These data showed that they had strong synergism at least (confidence interval ,0.3). We further investigated whether combination treatment could inhibit colony-formation capability. As shown in Figure 2B 
curcumin disrupts the nFκB-signaling pathway
To investigate the mechanism responsible for activation of NFκB signaling in SGCR cells, we examined the expression of TNFα, an important factor involved in NFκB signaling. 24 Quantitative RT-PCR analysis revealed that the amount of TNFα mRNA was greatly increased in SGCR/5-FU cells compared with parental SGC cells ( Figure 3A) . We further tested whether CM from 5-FU-treated SGC cancer cells or CM from cisplatin-treated SGC cells affected IκBα protein changes in naïve SGC cells. Preincubation of SGC cells with 5-FU-CM or cisplatin-CM significantly increased the degradation of IκBα ( Figure 3B ), indicating that 5-FU-CM and cisplatin-CM may have activated NFκB signaling. We reasoned that the presence of TNFα secretion in the cell-culture media could have dampened the response of SGC cells to 5-FU. Consequently, we examined the effect of exogenous TNFα in parental SGC cells. We observed that exposure to TNFα induced resistance to 5-FU in SGC cells (Figure 3D ), supporting the notion that increased secretion of TNFα can lead to the development of 5-FU resistance.
Next, we investigated the molecular mechanisms underlying the synergic effect of 5-FU and curcumin in SGCR/5-FU cells. We employed Western blot to test whether the NFκB-signaling pathway was involved in the curcumin-mediated 
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curcumin mediates chemosensitization to 5-FU anticancer effects. As shown in Figure 3E and F, following the exposure to curcumin, the protein level of the degradation of IκBα decreased significantly in proportion to the dosage of curcumin in SGCR/5-FU cells. The NFκB-signaling pathway has been shown to play an important role in various cancers. [25] [26] [27] Based on the results obtained, we further examined whether curcumin could inhibit the NFκB-signaling pathway in 5-FU-treated SGCR/5-FU cells. As we expected, curcumin efficiently suppressed NFκB activity in SGCR/5-FU cells ( Figure 3G and H) . Furthermore, curcumin inhibited activation of the NFκB survival-signaling pathway that resulted from 5-FU-CM ( Figure 3I and J). Our data 
Discussion
Curcumin has long been known to act as a therapeutic or preventive agent for the treatment of several major human cancers involved in a variety of antitumor cellular processes. 28, 29 It has been found that curcumin by oral administration had beneficial effects on several types of premalignant lesions. In a recent Phase I clinical trial, curcumin combined with standard docetaxel chemotherapy produced significant biological improvements and clinical response in patients with metastatic breast cancer. 19 Therefore, curcumin may have the potential as auxiliary treatment for other resistant cancers. We investigated whether curcumin could inhibit the activation of the NFκB survival-signaling pathway to reverse drug resistance to 5-FU and improve the efficacy in resistant GC cells. Our results showed that curcumin significantly sensitized GC cells to 5-FU treatment. SGC/5-FUR tumor cells exhibited remarkable sensitivities to curcumin-mediated apoptosis in vitro.
The underlying mechanisms for drug resistance to 5-FU treatment for GC patients are still not clear. Drug resistance can be induced by the activation of survival-signaling pathways. The NFκB-signaling pathway is one of the most important survival-signaling cascades involved in drug resistance in tumor cells. NFκB signaling has been found to be important for the growth of antiestrogen-resistant breast cancer cells. 30 Previous studies have also reported that the aberrant activation of NFκB signaling can induce drug resistance in cancer. 31, 32 For example, blockade of the NFκB-signaling pathway can overcome imatinib resistance. 32 Therefore, we hypothesized that the NFκB-signaling pathway may be involved in drug-resistance development in GC. In order to verify our hypothesis, we developed 5-FU-resistant (SGCR/5-FU) cell lines and found marked activation of NFκB signaling in SGCR/5-FU cells. We have confirmed that NFκB signaling played a major role in the 5-FU resistance of GC cells. Importantly, hyperactivated NFκB was detected in clinical specimens from GC patients. Our results are in agreement with other reports that curcumin can suppress NFκB activation. Therapy-induced tumor secretomes promote resistance and tumor progression. 33 We further investigated the correlation between the level of cytokine TNFα and the NFκB activation that mediates GC resistance. Increasing TNFα has been found to induce translocation of p65 into the nucleus and reverse tamoxifen-resistant breast cancer cells. 33 In our study, quantitative RT-PCR analysis revealed that TNFα was greatly increased in SGCR/5-FU cells compared with that in parental SGC cells. Treatment of sensitive SGC cells with CM-5-FU also activated the NFκB-signaling pathway. Such results suggest that cytokine TNFα was closely correlated to the abnormal activation of the NFκB-signaling pathway. We found that the increase in cytokine TNFα resulted from NFκB activation. Research has demonstrated that PI3K-driven NFκB activation leads to increased activation of nearby stromal cells, helping to generate a protumor microenvironment and facilitate tumor progression. 34 This research also indicated that NFκB plays diverse roles downstream from different oncogenic signaling pathways. Therefore, targeting NFκB has been attracting more attention as a novel preventive and therapeutic strategy against refractory human cancers.
Conclusion
Our results demonstrated that activation of the NFκB-signaling pathway may be a possible mechanism for resistance of 5-FU in GC cells. We identified that curcumin, a safe oral drug, can reverse 5-FU resistance and inhibit proliferation in GC cells by downregulating the NFκB-signaling pathway. Combination of curcumin and 5-FU resulted in synergistic antiproliferative effects and induced synergistically potent apoptosis in SGCR/5-FU cells. Our study provides a novel mechanism-based rationale for further animal experiments and clinical studies to confirm the combination therapy of curcumin and 5-FU in patients with GC.
